Suzetrigine - Vertex Pharmaceuticals
Alternative Names: VX-548Latest Information Update: 14 Oct 2024
At a glance
- Originator Vertex Pharmaceuticals
- Class 1 ring heterocyclic compounds; Amides; Analgesics; Ethers; Fluorinated hydrocarbons; Fluorobenzenes; Pyridines; Small molecules
- Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Acute pain
- Phase II Neuropathic pain
- Phase I Pain
Most Recent Events
- 08 Oct 2024 Vertex Pharmaceuticals plans a phase III trial for Neuropathic pain in (NCT06628908)
- 11 Sep 2024 Vertex Pharmaceuticals plans two pivotal phase III trials for diabetic peripheral neuropathy in third quarter of 2024
- 01 Aug 2024 Vertex Pharmaceuticals plans to launch suzetrigine in Acute pain in USA (PO)